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Objective: To determine if baseline measurements of
cerebral atrophy and severity of white matter hyperin-
tensity (WMH) predict the rate of future cognitive de-
cline in patients with Alzheimer disease (AD).
Design: Data were drawn from the Predictors Study, a
longitudinal study that enrolls patients with mild AD and
reassesses them every 6 months with use of the Colum-
bia modified Mini-Mental State (mMMS) examination
(score range, 0-57). Magnetic resonance images were ana-
lyzed to determine the severity of WMH, using the Scheltens
scale, and the degree of atrophy, using the bicaudate ra-
tio. Generalized estimating equations were used to deter-
mine whether severity of baseline magnetic resonance im-
age measurements and their interaction predicted the rate
of mMMS score decline at subsequent visits.
Setting: Three university-based AD centers in the United
States.
Participants: At baseline, 84 patients with AD from the
Predictors Study received structural magnetic reso-
nance imaging and were selected for analysis. They had
a mean of 6 follow-up evaluations.
Main Outcome Measure: The mMMS score.
Results: Generalized estimating equation models dem-
onstrated that the degree of baseline atrophy (=−0.316;
P=.04), the severity of WMH (=−0.173; P=.03), and
their interaction (=−6.061; P=.02) predicted the rate
of decline in mMMS scores.
Conclusions: Both degree of cerebral atrophy and se-
verity of WMH are associated with the rapidity of cog-
nitive decline in AD. Atrophy and WMH may have a syn-
ergistic effect on future decline in AD, such that patients
with a high degree of both have a particularly precipi-
tous cognitive course. These findings lend further sup-
port to the hypothesis that cerebrovascular pathological
abnormalities contribute to the clinical syndrome of AD.
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I N THE ABSENCE OF DEFINITIVE DI-agnostic instruments for Alzhei-mer disease (AD), structural mag-netic resonance imaging (MRI)has emerged as an important tool
for the characterization of morphological
changes associated with the disease.1 In-
creased atrophy, for example, is a consis-
tent structural neuroimaging finding that
is a hallmark of AD.2,3 Longitudinal analy-
ses revealed greater rates of brain atro-
phy among patients with AD than among
healthy adults4-6 and a correlation be-
tween the severity of atrophic change and
severity of cognitive deficits.2,7 These find-
ings suggest that measures of cerebral at-
rophy provide a reasonable marker for dis-
ease staging in AD.
Areas of increased intensity on T2-
weighted MRI sequences, including fluid-
attenuated inversion recovery (FLAIR)
sequences, called white matter hyperin-
tensities (WMHs), are thought to reflect
small vessel cerebrovascular disease8-12
and may contribute to age-associated cog-
nitive decline.13 Similar to the degree of
cerebral atrophy, WMHs are prevalent in
patients with AD,14 and the absence of neu-
roradiological markers of cerebrovascu-
lar disease among individuals with de-
mentia is rare.13
Whether evaluation of neuroimaging
data at one point has prognostic value to
determine future cognitive decline re-
mains an important question. Data from
the Cardiovascular Health Study15 showed
that baseline ventricular volumes were
larger among individuals who progressed
from neurological health to dementia dur-
ing a 4-year period. In one study,16 ven-
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tricular volume and severity of WMH predicted the rate
of future decline among healthy older adults, but only
ventricular volume predicted the rate of decline among
those with mild cognitive impairment and AD. How-
ever, only 39 patients with AD were included in the study,
and the investigators did not examine the interaction be-
tween ventricular volume and WMH severity. Examin-
ing the 2 imaging markers together may help determine
the relative importance of cerebrovascular disease in the
course of AD and whether it synergistically interacts with
disease state.
In the current study, we used data from the Predictors
Study cohort17-19 to examine the prognostic utility of base-
line measurements of atrophy and cerebrovascular dis-
ease on rates of cognitive decline among individuals in the
early stages of AD. An overarching goal of the Predictors
Study is to elucidate the determinants of the cognitive and
functional course of AD. A subset of participants re-
ceived standard MRI studies as part of their diagnostic
workup. We used these data and rated the severity of ce-
rebral atrophy and WMH to predict future decline in cog-
nitive abilities. We hypothesized that baseline atrophy and
WMH ratings would predict future decline in cognition
and that the 2 measures would interact.
METHODS
SAMPLE CHARACTERISTICS
The sample was drawn from the Predictors Study cohort and
included individuals with AD.20,21 Complete inclusion criteria
and other details of the study are described elsewhere.17,18 Briefly,
participants met diagnostic criteria for dementia of the Alzhei-
mer type21 and probable AD.20 Exclusion criteria included par-
kinsonism, stroke, alcoholism, schizophrenia, schizoaffective
disorder, and history of electroconvulsive treatments. Partici-
pants were recruited from Columbia University, Johns Hop-
kins School of Medicine, and Massachusetts General Hospital
between April 1989 and September 2005. The study was ap-
proved by local ethics committees. Neuroimaging was ac-
quired for clinical diagnostic purposes, and images were avail-
able for 84 individuals in the study cohort. These subjects
constitute the current study sample. Mean (SD) age at the time
of the neuroimaging study was 73.2 (8.0) years; 40 subjects
(48%) were male, and 76 (90%) were white. Mean (SD) num-
ber of years of education was 14.8 (3.7). Participants were
relatively mildly impaired at the time of their neuroimaging stud-
ies, as indicated by a mean (SD) Columbia modified Mini-
Mental State (mMMS) examination score of 41.3 (7.1), which
is comparable to a Mini-Mental State Examination (MMSE)22
score of approximately 22. The mean (SD) number of fol-
low-up visits, at approximate 6-month intervals, was 5.8 (3.0).
Of 62 subjects for whom data were available, 31 (50%) had the
apolipoprotein E ε4 (APOE ε4) allele. At baseline, 8 of 84 (10%)
had a self-reported history of diabetes mellitus, 14 (17%) had
dyslipidemia, 14 (17%) had coronary artery disease, and 30
(36%) had hypertension. Compared with the participants with-
out available neuroimages (n=456) in the Predictors Study, the
current study participants were similar in age, sex, number of
evaluations, and proportion with the APOE ε4 allele, diabetes
mellitus, dyslipidemia, coronary artery disease, and hyperten-
sion. Those without available neuroimages had fewer years of
education than those with available neuroimages (mean [SD],
13.4[3.5] vs 14.8[3.7]; t537=3.192; P=.001).
NEUROIMAGING
Estimates of total brain atrophy were computed primarily from
T1-weighted images, which were available for 53 (63%) of 84
participants with neuroimaging data; atrophy measurements were
computed for the remaining participants on FLAIR–, proton-,
or T2-weighted images. Findings did not change when we in-
cluded image sequence as a dummy-coded covariate. Bicaudate
ratios were derived from axially acquired images as an estimate
of total brain atrophy following established protocols.23-25 To de-
rive the bicaudate ratio, the axial slice on which the caudate nu-
clei produced the greatest amount of indentation on the lateral
ventricles was identified, and the distance between the 2 cau-
date apices was measured in millimeters. This value was di-
vided by the maximum width of the skull at the same level as
the caudate measurement (Figure1). Using this approach, en-
larged ventricles increase the distance between the 2 caudate nu-
clei, resulting in a higher bicaudate ratio. Therefore, a larger value
indicates a greater degree of atrophy. Bicaudate ratio measure-
ments were made by 2 experienced raters (A.M.B. and L.S.H.).
Interrater reliability, computed for 12 images, was good for bi-
caudate distance (intraclass correlation coefficient,0.861), skull
width (0.991), and bicaudate ratio (0.740). Furthermore, in an
independent sample of digital T1-weighted MRIs from 17 pa-
tients with dementia, we calculated bicaudate ratios and com-
pared them with manually derived full relative brain volumes
and found a strong relationship between the 2 measures (Spear-
man ,−0.814; P .001). These findings suggest that the bicau-
date ratio is a reliable and valid index of cerebral atrophy.
The WMH severity ratings were attained from FLAIR– and
T2-weighted images using the Scheltens scale.26 The Scheltens
scale is a visual rating scale that includes anchored 7-point se-
verity ratings in periventricular (ie, frontal horn, occipital horn,
and lateral bands), cortical (ie, frontal, temporal, parietal, and
Figure 1. The bicaudate ratio is calculated by dividing the ventricular
dimension (the distance between the 2 apices of the caudate nuclei; yellow
bar) by the inner skull dimension (turquoise line). A higher ratio indicates
greater atrophy. A indicates anterior; L, left; P, posterior; R, right.
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occipital lobes), subcortical (ie, caudate, putamen, globus pal-
lidus, internal capsule, and thalamus), and infratentorial (ie,
mesencephalon, pons, medulla, and cerebellum) regions. The
WMH severity measure for the current study was the sum of
ratings for the 4 regions. All WMH ratings were performed by
one rater (L.S.H.). Intrarater reliability, computed for 12 im-
ages, was high (intraclass correlation coefficient,0.912).
CLINICAL EVALUATION
Performance on the mMMS27 was the primary outcome mea-
sure. The mMMS is an expanded version of the MMSE22 and
consists of attention/calculation, general knowledge, lan-
guage, and construction tasks. The scale has a maximum score
of 57. All participants in the Predictors Study were required to
score 30 or higher for inclusion, which is equivalent to a score
of about 16 on the MMSE. The mMMS was administered at each
semiannual visit and served as the indicator of cognitive change.
Additional risk factor clinical data included presence or ab-
sence of the following variables:APOE-ε4 allele,28 diabetes melli-
tus, dyslipidemia, coronary artery disease, and hypertension,
which were coded as present based on reported history of treat-
ment or diagnosis.
STATISTICAL ANALYSIS
Baseline associations between MRI-derived measurements and
cognition were evaluated with multiple linear regression analy-
ses. First, baseline bicaudate ratio, age, sex, educational level,
and risk factor variables were entered as independent vari-
ables, and total score on the mMMS was the dependent vari-
able. The model was conducted again without the risk factors.
Next, the same 2 regression analyses were conducted substi-
tuting Scheltens scale WMH severity ratings for the bicaudate
ratio. Finally, the same 2 regression analyses were conducted
with WMH ratings, atrophy ratings, and their interaction term.
A similar approach was taken to evaluate the effect of base-
line atrophy and WMH severity on longitudinal change in cog-
nition. A series of generalized estimating equations (GEEs)29
tested associations between baseline bicaudate ratio or WMH
severity and change in mMMS score with and without risk fac-
tor covariates. This approach takes into account multiple vis-
its per subject and the likelihood that characteristics of the same
individuals over time are correlated. To establish the rate of cog-
nitive decline, the first GEE model was run with mMMS score
as the dependent variable and time (in years from baseline) as
the independent variable. In all subsequent GEE models, mMMS
score was the dependent variable, and the MRI measurement
(ie, Scheltens scale score or bicaudate ratio), time, and an MRI
measurement  time interaction term were included as pre-
dictors. All models included age, sex, and educational level as
additional covariates. In a final GEE model, we included WMH
severity ratings and bicaudate ratios, their interaction terms with
time, and their 3-way interaction (ie, bicaudate ratio Scheltens
scale score time) to evaluate their combined effects on cog-
nitive decline. The 3 models were run with and without risk
factor variables as additional covariates. Significant main ef-
fects of MRI measurements would indicate a difference in cog-
nitive performance for each unit of measurement. A signifi-
cant time effect would indicate a change in test scores over time.
A significant interaction term with time would indicate differ-
ential rates of change in cognition over time as a function of the
MRI measurement. Finally, a significant 3-way interaction would
suggest an interaction of the 2 MRI measurements with time.
RESULTS
BASELINE ASSOCIATIONS WITH COGNITION
Mean (SD) bicaudate ratio and WMH ratings were 0.16
(0.02) and 3.79 (4.55), respectively. The overall mul-
tiple regression model testing the baseline association of
atrophy with cognition was significant (F9,55=2.357;
P=.03), although only increased number of years of edu-
cation entered into the model as a predictor of higher
mMMS scores (=1.161; SE,0.307; P .001).
Table. GEE Analyses to Test the Effects of Cerebral Atrophy and GEE on Rate of Cognitive Decline
Variable
Model 1a Model 2b
 P Value  P Value
Atrophy
Timec 1.619 .49 2.964 .12
Bicaudate ratio −0.786 .02 −0.497 .09
Timecbicaudate ratio −0.316 .04 −0.415 .001
WMH
Timec −2.706 .001 −3.160 .001
Scheltens scale score −0.082 .68 −0.106 .56
TimecScheltens scale score −0.173 .03 −0.122 .71
Atrophy and WMH
Timec −1.988 .30 0.977 .50
Bicaudate ratio −0.445 .15 −0.427 .12
Scheltens scale score −0.224 .25 −0.145 .36
Timecbicaudate ratio −6.277 .62 −0.278 .003
TimecScheltens scale score 0.968 .05 0.512 .09
Timecbicaudate ratioScheltens scale score −6.061 .02 −3.250 .05
Abbreviations: GEE, generalized estimating equation; WHM, white matter hyperintensity.
aAdjusted for age, sex, educational level, apolipoprotein E ε4 allele, diabetes mellitus, dyslipidemia, coronary artery disease, and hypertension.
bAdjusted for age, sex, and educational level.
cThe main effect of “time” shows the rate of change in modified Mini-Mental State (mMMS) score per 1-year interval as a function of each unit of the
independent variable. For example, the “timebicaudate ratio” interaction shows the effect of baseline atrophy measures on the annual rate of change in mMMS
score (ie, for every 1% increase in baseline bicaudate ratio, there is an associated 0.316-point decrease in mMMS score per year).
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The regression model testing the association of WMH
severity with baseline cognition was not significant with
(F9,53=1.981; P=.07) or without (F4,76=2.302; P=.07) risk
factor variables included. Similarly, when the 2 MRI mea-
surements and their interaction terms were included, the
model was not significant whether risk factor variables
were (F11,53 =1.898; P=.07) or were not (F6,76=1.960;
P=.08) included.
In a separate bivariate correlational analysis, control-
ling for age, severity of WMH was not significantly as-
sociated with atrophy ratings (r74=0.103; P=.38).
LONGITUDINAL ANALYSIS
The mMMS scores declined a mean of 3.5 points per year
(estimated =−3.455; P .001). The Table displays the
primary results of the 3 GEE analyses. For every 1% in-
crease in baseline bicaudate ratio, there was an addi-
tional associated 0.316-point decrease in mMMS score
per year (significant time  bicaudate interaction). In-
creased age (=0.452; P=.04), being male (=5.263;
P=.04), and lower educational level (=1.239; P .001)
were associated with poorer mMMS scores. The effect of
bicaudate ratio on mMMS score decline was similar when
the vascular risk factors were excluded. Figure 2 dis-
plays the estimated rate of decline in mMMS scores in
participants with low and high bicaudate ratio values,
which were defined on the basis of a median split (me-
dian ratio, 0.1567).
A similar pattern emerged when examining the effect
of baseline WMH severity on future decline. For each
Scheltens scale point (ie, increase in WMH severity), there
was an additional 0.173-point loss in mMMS score per
visit (significant WMH time interaction) (Figure 3).
Being male (=4.801; P=.04) and lower educational level
(=1.018; P=.002) were associated with lower mMMS
scores. None of the risk factor variables reached signifi-
cance for this model. When they were removed from the
analysis, the findings remained essentially unchanged,
although the significance of the time  WMH interac-
tion was reduced to a trend-level effect.
When we examined the combined effect of baseline at-
rophy and WMH severity on future decline, a significant
3-way interaction indicated that individuals with the high-
est severity of WMH and greatest atrophy had the most
precipitous rate of cognitive decline (Table and Figure4).
Excluding the vascular risk factors, the 3-way interaction
remained statistically significant, and baseline atrophy rat-
ings significantly predicted rate of decline.
COMMENT
The current study sought to determine whether mea-
sures of cerebral atrophy and WMH were associated with
cognitive function and the rate of future cognitive de-
cline in AD. Several important findings emerged. First,
when examined cross-sectionally, increased atrophy was
modestly associated with poorer cognitive perfor-
mance, but the relationship between severity of WMH
and cognition was unremarkable. When examined lon-
gitudinally, severity of baseline atrophy and severity of
baseline WMH were associated with a faster rate of fu-
ture cognitive decline. When both severity measures were
considered in the same statistical model, they interacted
and had an effect on future decline. Taken together, the
findings suggest a synergistic interaction of AD pathol-
ogy and small vessel vascular disease on the course of
cognitive symptoms in AD.
The results add to a growing corpus of work examin-
ing the associations among measures of AD pathology, vas-
cular disease, and their clinical expression. In most stud-
ies, atrophy is more prominent among patients with AD
than controls1-3,30 and is associated with more severe cog-




















Figure 2. Predicted rates of cognitive change based on baseline
characterization of bicaudate ratio. Baseline bicaudate ratio is presented as a
dichotomous variable based on the median split of the entire sample
(median,0.1567). Note that a higher bicaudate ratio indicates greater amount
of atrophy. The results from the generalized estimating equation analysis
suggest that the greater the amount of atrophy at baseline, the greater the



















Figure 3. Predicted rates of cognitive change based on baseline
characterization of white matter hyperintensity (WMH) severity. Baseline
Scheltens scale score is presented as a dichotomous variable based on the
median split of the entire sample (median,3.0). The results from the
generalized estimating equation analysis suggest that the higher and more
severe the baseline WMH, the greater the rate of cognitive decline.
mMMS indicates modified Mini-Mental State.
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atrophy is associated with future risk of developing AD15,33,34
and that the rate of regional atrophy predicts decline among
patients with mild cognitive impairment and AD.35,36 The
current study extends these findings. Although cross-
sectional associations with cognitive abilities were weak,
global atrophy was robustly associated with a more pre-
cipitous cognitive decline. The findings suggest that, among
individuals with mild AD, the severity of pathology-
associated atrophy at one point in time has prognostic util-
ity. Whole brain atrophy is not specific to the diagnosis
of AD; however, within a sample of well-defined patients
with AD, it is a good marker of disease severity. Thus, the
current study supports previous cognitive studies show-
ing an accelerated rate of future decline among more se-
verely affected patients with AD.37
White matter hyperintensity burden has been re-
ported to be more severe among patients with AD than
nondemented elderly persons,3,14,38 although not all stud-
ies have shown this association.39,40 Furthermore, some
studies have shown that increased burden is associated
with poorer cognitive abilities in AD,41,42 whereas oth-
ers have not,40,43,44 but the relationship between severity
of WMH and cognitive abilities among older adults with-
out dementia has been more consistently demon-
strated.42,45-47 It is possible that small vessel vascular dis-
ease, reflected in the severity of WMH, significantly affects
cognitive abilities among individuals with no or very little
AD pathology. Among those with more severe manifes-
tations of disease, AD pathology may play a more sa-
lient role in cognitive abilities, effectively concealing the
effect of small vessel vascular disease. Our results par-
tially support this idea: on a cross-sectional basis, the se-
verity of WMH was not associated with severity of cog-
nitive impairment
Our findings are consistent with the idea that cere-
brovascular pathology interacts with AD pathology.
Whereas severity of baseline atrophy and severity of base-
line WMH were associated with the rate of cognitive de-
cline, when the 2 measures were included in the same
model, the interaction effect was significant and the in-
dividual main effects were not. The observation is remi-
niscent of autopsy studies that have shown that indi-
viduals with vascular disease and AD pathology were more
likely to have clinical dementia compared with those with-
out vascular disease48 or findings that less AD pathology
is required to produce the same degree of cognitive im-
pairment when vascular disease is present.49 Our find-
ings are most consistent with a report50 that demon-
strated a significant interaction of WMH and medial
temporal lobe atrophy in the classification of older adults
as AD or being normal; the risk associated with having a
high degree of atrophy and a high degree of WMH was
greater than the risk incurred by the product of the 2 fac-
tors. Although we did not observe an interaction be-
tween degree of atrophy and WMH cross-sectionally, the
significant effect on future decline suggests a synergis-
tic interaction of the 2 pathologies on the course of AD.
From a mechanistic perspective, the interaction of cere-
brovascular and AD pathology may be a reflection of -
amyloid (A) peptide deposition, which comprises the
senile plaques characteristic of AD pathology, in the A42
species, and cerebrovascular amyloid, in its A40 form.
Indeed, plasma concentrations of A40 peptide were as-
sociated with increased WMH volume among patients
with AD and cerebral amyloid angiopathy in a clinic-
based sample51 and among participants in the population-
based Rotterdam Study.52 In the current study, WMH se-
verity predicted rate of cognitive decline among patients
with AD only after statistical adjustment for common vas-
cular risk factors (Table), suggesting that the variance
in WMH related to cognitive course in AD is not owing
to these risk factors. Rather, it is possible that WMH-
associated cerebrovascular A deposition specifically ac-
counts for this association. Future work should exam-
ine the association among concentrations of plasma A,
WMH, and longitudinal changes in cognition.
Although inconsistencies exist in the literature re-
garding the exact relationship among AD pathological
characteristics, vascular abnormalities, and cognition, find-
ings do converge in demonstrating that increased cere-
brovascular disease burden is not beneficial and is most
likely harmful. At present, there are no available disease-
modifying treatments for AD. However, there are a num-
ber of potentially modifiable risk factors and behaviors
for cerebrovascular disease.53-55 The reduction of these







































Figure 4. Graphical representation of the significant time  baseline white
matter hyperintensity (WMH)  baseline atrophy interaction. The WMH
severity and low (A) and high (B) degree of atrophy groups are based on the
median severity. The predicted modified Mini-Mental State (mMMS) scores
declined most precipitously among individuals with greater levels of atrophy
and greater baseline WMH burden (B).
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ment of the cognitive symptoms associated with AD, and
further study of the determinants of WMH among pa-
tients with AD may highlight newer treatment targets.
This study has several limitations. First, neuroimag-
ing was available for only a subset of participants in the
Predictors Study, although participants with and with-
out neuroimaging were similar. Second, analyses were
conducted on ratings of clinical MRI scans, as opposed
to digital scans that were acquired uniformly and ana-
lyzed automatically. Because clinical scans were ac-
quired in the axial orientation, our analyses focused on
global atrophy as opposed to atrophy in areas more spe-
cific to AD, such as the medial temporal lobe, which would
require scans oriented in the coronal plane. Newer pro-
tocols exist that are able to quantify regional atrophy and
WMH signal with higher precision and accuracy. It should
be noted, however, that rater reliability for the bicau-
date ratio and Scheltens scale was high and that esti-
mates of atrophy from the bicaudate ratio were highly
correlated with whole-brain atrophy measures derived
in an independent sample. Third, although the study in-
cluded well-characterized longitudinal cognitive data, neu-
roimaging data were only available at one point in time,
thus limiting inference about the emergence and evolu-
tion of the imaging markers themselves. Future studies
should incorporate prospectively collected longitudinal
clinical and neuroradiological data.
This study also has a number of particular strengths.
To our knowledge, this is among the largest studies that
have examined prognostic utility of baseline neuroim-
aging characteristics on future cognitive decline in AD.
Patients were carefully diagnosed at academic medical
centers with specific expertise in aging and dementia,
and diagnoses were based on uniform application of
widely accepted criteria via consensus diagnosis proce-
dures. Diagnoses from the Predictors Study are accu-
rate. For example, 93% of patients that came to autopsy
had pathologically confirmed AD at postmortem evalu-
ation.56 Patients were evaluated prospectively and rela-
tively frequently (ie, biannually). Because participants
were generally mildly demented at their baseline evalu-
ation, we were able to capture a large range of progres-
sion over time.
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